> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# GLP-1 agonists and atrial fibrillation in non-diabetic obesity with kidney disease
- URL: https://www.coios.me/glp-1-agonists-and-atrial-fibrillation-in-non-diabetic/
- Published: 2026-10-19T11:45:48.000Z
- Updated: 2026-10-19T12:37:48.000Z
- Description: GLP-1 users with obesity and CKD had 1.63% one-year incident atrial fibrillation, against 2.62% in unexposed patients.
- Author: Daniel Ryan
- Tags: Health today, Obesity, diabetes and GLP-1, Heart and stroke, United States, #peer-reviewed, #new, #item, #source-2026-10, #score-58

The study emulated a target trial in TriNetX US network records, 2021-2024\. Non-diabetic adults with obesity and chronic kidney disease stages 3-5 were included. Semaglutide, liraglutide or tirzepatide users were matched to unexposed patients, 7,326 per cohort. One-year incident atrial fibrillation was 1.63% versus 2.62%, hazard ratio 0.655 (95% CI 0.508-0.844). Ventricular tachyarrhythmias (HR 0.556) and all-cause hospitalisation (HR 0.668) were also lower. Being retrospective, confounding by indication and unmeasured prescribing differences cannot be excluded.

*Why it is interesting: It extends GLP-1 receptor agonist outcomes beyond diabetes to a cardiorenal group. Atrial fibrillation, ventricular arrhythmias and hospitalisation were all lower in treated patients.*

Source

[International Journal of Cardiology, 18 October 2026](https://doi.org/10.1016/j.ijcard.2026.135000?ref=coios.me)

Paper

GLP-1 receptor agonist therapy and incident atrial fibrillation in non-diabetic adults with obesity and chronic kidney disease: a propensity matched cohort study

Authors

Hassan A, Okorigba E, Grace C, Otabor E, Osineye B, Olayiwola O et al.

DOI

10.1016/j.ijcard.2026.135000

Type

Peer-reviewed article

Design

Retrospective target trial emulation, TriNetX US network (66 organisations), non-diabetic adults with obesity and CKD 3-5 diagnosed 2021-2024; 10,985 exposed vs 94,527 unexposed, 7,326 per arm after propensity matching; 1-year primary outcome with 2-3 year sensitivity analyses

Verdict

New finding

Driver

[Obesity, diabetes and GLP-1](https://www.coios.me/d-obesity-diabetes/)

Driver

[Heart and stroke](https://www.coios.me/d-cardiovascular/)